Citations

Showing 10 of 108081 citations.

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database
Renfro, Lindsay A. , Goldberg, Richard M. , Sobrero, Alberto , Adams, Richard , Seymour, Michel , Heinemann, Volker , Schmoll, Hans‐Joachim , Douillard, Jean‐Yves , Hurwitz, Herbert I. , Fuchs, Charles S. , Díaz‐Rubio, Eduardo , Porschen, Rainer, Tournigand, Christophe , Chibaudel, Benoist , Hoff, Paulo M. , Kabbinavar, Fairooz F. , Falcone, Alfredo , Punt, Cornelis J.A. , Hecht, J. Randolph, Souglakos, John , Bokemeyer, Carsten , Gramont, Aimery de , Seymour, Matthew T, Hurwitz, Herbert, Díaz-Rubio, Eduardo, Tebbutt, Niall C. , van Cutsem, Eric, Saltz, Leonard, de Gramont, Aimery, Grothey, Axel , Cutsem, Eric Van , Saltz, Leonard B. , Sargent, Daniel J. , Falcone, Alfredo , Seymour, Matthew T , Adams, Richard , Schmoll, Hans-Joachim , Chibaudel, Benoist

Mayo Clinic

Journal of Clinical Oncology | April 17, 2017 | Volume: 35 | Issue: 17 | Pages: 1929-1937

10.1200/jco.2016.71.5771 | PMID 28414610 Get It

Purpose Factors contributing to early mortality after initiation of treatment of metastatic colorectal cancer are poorly understood. Materials and Methods Data from 22,654 patients enrolled in 28 randomized phase III trials contained in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were pooled. Multivariable logistic regression models for 30-, 60-, and 90-day mortality were constructed, including clinically and statistically significant patient and disease factors and interaction terms. A calculator (nomogram) for 90-day mortality was developed and validated internally using bootstrapping methods and externally using a 10% random holdout sample from each trial. The impact of early progression on the likelihood of survival to 90 days was examined with time-dependent Cox proportional hazards models. Results Mortality rates were 1.4% at 30 days, 3.4% at 60 days, and 5.5% at 90 days. Among baseline factors, advanced age, lower body mass index, poorer performance status, increased number of metastatic sites, BRAF mutant status, and several laboratory parameters were associated with increased likelihood of early mortality. A multivariable model for 90-day mortality showed strong internal discrimination (C-index, 0.77) and good calibration across risk groups as well as accurate predictions in the external validation set, both overall and within patient subgroups. Conclusion A validated clinical nomogram has been developed to quantify the risk of early death for individual patients during initial treatment of metastatic colorectal cancer. This tool may be used for patient eligibility assessment or risk stratification in future clinical trials and to identify patients requiring more or less aggressive therapy and additional supportive measures during and after treatment.
The 2016 revised World Health Organization definition of ‘myelodysplastic syndrome with isolated del(5q)’; prognostic implications of single versus double cytogenetic abnormalities
Gurney, Mark E. , Patnaik, Mrinal M. , Hanson, Curtis A. , Litzow, Mark R. , Al‐Kali, Aref , Ketterling, Rhett P. , Tefferi, Ayalew , Gangat, Naseema , Gurney, Mark , Ketterling, Rhett P

Mayo Clinic

British Journal of Haematology | April 17, 2017 | Volume: 178 | Issue: 1 | Pages: 57-60

10.1111/bjh.14636 | PMID 28419466 Get It

SummaryThe definition of the myelodysplastic syndrome (MDS) subtype ‘MDS with isolated del(5q)’ was expanded to include cases with one additional non‐chromosome 7 based cytogenetic abnormality in the 2016 revised World Health Organization classification. This study applied the revised definition to a large primary MDS cohort, and evaluated the prognostic impact of the additional cytogenetic abnormality. Seventy‐two of 1067 patients (7%) met the ‘MDS with isolated del(5q)’ criteria, 11 (1%) of whom had an additional cytogenetic abnormality. There was no survival difference between patients in whom del(5q) occurred alone, compared to those with one additional cytogenetic abnormality (P = 0·52).
Feeling run down: exercise‐induced pancytopenia
Huffman, Brandon M. , Wiisanen, Jeff, Shi, Min , Go, Ronald S.

Mayo Clinic

British Journal of Haematology | April 17, 2017 | Volume: 177 | Issue: 5 | Pages: 672-672

10.1111/bjh.14648 | PMID 28419423 Get It

Helicobacter Pylori Infection in Texas Hispanic and Non-Hispanic White Men: Implications for Gastric Cancer Risk Disparities
Parma, Dorothy Long , Muñoz, Edgar , Ogden, Susan M., Westin, Gustavo Figueiredo Marcondes, Leach, Robin J. , Thompson, Ian M. , Westin, Gustavo F, Ramirez, Amelie G , Thompson, Ian M

Mayo Clinic

American Journal of Men's Health | April 17, 2017 | Volume: 11 | Issue: 4 | Pages: 1039-1045

10.1177/1557988317702038 | PMID 28413904 Get It

Chronic Helicobacter pylori ( H. pylori) infection is a major gastric adenocarcinoma (GA) risk factor. GA disproportionately affects U.S. Hispanics compared with non-Hispanic Whites (NHWs). Since H. pylori infection studies in Hispanics are few, infection rates in Hispanic and NHW men in Bexar County were compared, and relationships with ethnicity and obesity examined. Age- and zip code-matched participants from a community-dwelling cohort were randomly selected. Sera from 284 men were analyzed by enzyme immunoassay for H. pylori antibodies. Adjusted risk ratio estimation for matched data was conducted to identify differences. Hispanics had a markedly higher prevalence of infection (30.3%) than NHWs (9.2%). Matched risk ratio (mRR) analyses revealed a strong association between H. pylori seropositivity and Hispanic ethnicity (mRR = 3.31; 95% CI [1.91, 5.73], adjusted by BMI, smoking status, and family history of cancer (mRR range = 3.28-3.89). BMI mRRs (range = 1.19-1.22) were significant in all models. In this cohort, Hispanic men had higher H. pylori infection rates than NHWs, and parallel the disproportionately higher rates of GA; obesity contributes to this higher prevalence. Future studies should address country of origin, acculturation, and other factors influencing obesity to further elucidate risk of GA in Hispanic populations.
Dual-Energy CT Differentiates Contrast Staining From Hemorrhagic Conversion of Ischemic Stroke
Johnson, Derek R. , Campeau, Norbert G. , Johnson, Derek R

Mayo Clinic

The Neurohospitalist | April 16, 2017 | Volume: 8 | Issue: 1 | Pages: 42-43

10.1177/1941874417704754 | PMID 29276564 Get It

Type Iγ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κB
Xue, Junli , Chen, Chunhua , Qi, Manlong, Wang, Lin , Gao, Yong , Ling, Kun , Huang, Yan , Dong, Haidong

Mayo Clinic

Oncotarget | April 15, 2017 | Volume: 8 | Issue: 26 | Pages: 42414-42427

10.18632/oncotarget.17123 | PMID 28465490 Get It

Interpreting National Databases on Mechanical Circulatory Support
Vallabhajosyula, Saraschandra , Narayan, Aarti, Mankad, Sunil , Schears, Gregory J. , Jentzer, Jacob C. , Vallabhajosyula, Saraschandra

Mayo Clinic

Critical Care Medicine | April 15, 2017 | Volume: 45 | Issue: 5 | Pages: e532-e532

10.1097/ccm.0000000000002297 | PMID 28410319 Get It

Evaluating Automated Rules for Rapid Response System Alarm Triggers in Medical and Surgical Patients
Morlan, Bruce W., Johnson, Matthew G. , Hickman, Joel , Kirkland, Lisa L., Naessens, James M. , Romero‐Brufau, Santiago , Huddleston, Jeanne M.

Mayo Clinic

Journal of Hospital Medicine | April 15, 2017 | Volume: 12 | Issue: 4 | Pages: 217-223

10.12788/jhm.2712 | PMID 28459899 Get It

BACKGROUNDThe use of rapid response systems (RRS), which were designed to bring clinicians with critical care expertise to the bedside to prevent unnecessary deaths, has increased. RRS rely on accurate detection of acute deterioration events. Early warning scores (EWS) have been used for this purpose but were developed using heterogeneous populations. Predictive performance may differ in medical vs surgical patients.OBJECTIVETo evaluate the performance of published EWS in medical vs surgical patient populations.DESIGNRetrospective cohort study.SETTINGTwo tertiary care academic medical center hospitals in the Midwest totaling more than 1500 beds.PATIENTSAll patients discharged from January to December 2011.INTERVENTIONNone.MEASUREMENTSTime‐stamped longitudinal database of patient variables and outcomes, categorized as surgical or medical. Outcomes included unscheduled transfers to the intensive care unit, activation of the RRS, and calls for cardiorespiratory resuscitation (“resuscitation call”). The EWS were calculated and updated with every new patient variable entry over time. Scores were considered accurate if they predicted an outcome in the following 24 hours.RESULTSAll EWS demonstrated higher performance within the medical population as compared to surgical: higher positive predictive value (P < .0001 for all scores) and sensitivity (P < .0001 for all scores). All EWS had positive predictive values below 25%.CONCLUSIONSThe overall poor performance of the evaluated EWS was marginally better in medical patients when compared to surgical patients.
Decision-Making For Patients With Resectable Breast Cancer: Individualized Decisions For and By Patients and Their Physicians
Loprinzi, Charles L. , Ravdin, Peter M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 14, 2017 | Volume: 1 | Issue: 2 | Pages: 189-196

10.6004/jnccn.2003.0017 | PMID 19768877 Get It

Decisions regarding the use of adjuvant cytotoxic and hormonal therapies for women with breast cancer ideally should be made jointly by the patient and oncologist. For patients to be adequately involved in this decision-making process, they must be provided with appropriate education regarding the potential benefits and risks of adjuvant therapies. The recommended steps for doing this are: 1) understand baseline prognosis with locoregional therapy (surgery, radiation, or both) alone for the individual patient at hand; 2) determine the estimated benefit afforded by adjuvant therapy options for the individual patient; 3) estimate the risk of side effects of adjuvant therapy options; 4) convey the above information to the individual patient; 5) facilitate the individual patient's decision regarding adjuvant systemic therapy; and 6) support the patient's decision. Two computer-based tools (Numeracy and Adjuvant!) are available to facilitate this process.
269 Cardiac resynchronization therapy does not reduce the incidence of ventricular arrhythmias
Lin, Grace , Brady, Peter A. , Webster, Tracy L., Rea, Robert F., Hammill, Stephen C., Hayes, David L.

Mayo Clinic

EP Europace | April 14, 2017 | Volume: 7 | Issue: Supplement_1 | Pages: 64-65

10.1016/eupace/7.supplement_1.64-b Get It